This week's research roundup features: Progression of chronic kidney disease following radical and partial nephrectomy
Michael Baisch has been a systems engineer in the Department of Laboratory Medicine and Pathology (DLMP) at Mayo Clinic for 18 years. Michael partners with the laboratories and business offices to evaluate their workflows for optimal quality, efficiency, and cost. He strives to improve processes so the entire team can get results into the hands of the patient and their care team in an accurate, timely, and cost-effective manner.
This week's research roundup features: Renin production by juxtaglomerular cell tumors and clear cell renal cell carcinoma and the role of angiotensin signaling inhibitors
Utilizing testing capabilities of two separate laboratory facilities, Mayo Clinic Laboratories’ new serotonin release assay (SRA) is a gold-standard test supported by decades of clinical hematopathologic experience and advanced mass spectrometry testing.
This week's research roundup features: Evaluating the significance of pancreatobiliary fluorescence in situ hybridization polysomy on prognosis in de novo cholangiocarcinoma
Since overcoming a life-threatening diagnosis five years ago, Jim Smith has embraced life. But each time he travels to Mayo Clinic for follow-up laboratory testing, a well of emotions rises up to remind him of life’s fragility. Thankfully, through streamlined, accurate testing and top-notch clinical care, those feelings are generally short-lived.
As an event management coordinator for the Department of Laboratory Medicine and Pathology at Mayo Clinic, Jason Majorowicz acts as an investigator when something may deviate from its established process. With a background in biotechnology and over 20 years of experience at Mayo Clinic, Jason helps with process improvement, quality assurance, and problem-solving.
This week's research roundup features: Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations
This week's research roundup features: Automated scoring of total inflammation in renal allograft biopsies
Elise Bieri Patzke has worked at Mayo Clinic for 17 years and is currently a project manager in Mayo Clinic BioPharma Diagnostics. She enjoys collaborating with her laboratory colleagues to pursue test development projects and biopharma opportunities that support the advancement of health care.
This week's research roundup features: How do I warm HPC(A) products to maximize cell viability in the setting of cold agglutinin disease?
In a groundbreaking study, Mayo Clinic investigators have developed a multiomic molecular method to predict clinical COVID-19 (SARS-CoV-2) outcomes better than traditional cytokines. Using a machine-learning-based prediction model, the team identified 102 biomarkers, which include several novel cytokines and other proteins, lipids, and metabolites. The discovery may help clinicians reliably predict a more severe course of COVID-19 before the patient gets sick enough to be hospitalized. Until now, there have been no biomarkers that can reliably predict which patients are more likely to have severe illness.
This week's research roundup features: Transcriptomic analysis of cirrhosis-like hepatocellular carcinoma reveals distinct molecular characteristics and pathologic staging implications